At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
Roni Mamluk, Ph.D., Founder and Chief Executive Officer, Ayala Pharmaceuticals
“People living with rare and aggressive cancers have an enormous unmet need. We are working to bring a new treatment option to market that can make a true difference in the lives of these individuals and their families.”